ChemoCentryx (CCXI) Reports Publication of Positive Data from Phase 2 CARAT-2 for CCX354
Tweet Send to a Friend
ChemoCentryx, Inc. (Nasdaq: CCXI) announced today publication of positive data from the Company's Phase 2 CARAT-2 study for CCX354, a ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
